Changes in R&D leadership at Roche, Daiichi, ALK-Abelló

From Basel to Tokyo, multiple biopharmas are installing or seeking new R&D leadership.

John Tsai will succeed Ken Takeshita as global head of R&D at Daiichi Sankyo Co. Ltd. (Tokyo:4568) on April 1. Tsai, who joins from VC firm Syncona Ltd. (LSE:SYNC), was president and head of global drug development and CMO at Novartis AG (SIX:NOVN; NYSE:NVS), and has held prominent roles at Amgen Inc. (NASDAQ:AMGN) and Bristol Myers Squibb Co. (NYSE:BMY)...